Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico , in vitro, and in vivo analysis
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgae112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Faraha Ahmed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Hauptthemen laut MEDLINE: Uracil, Osteogenesis, Piperidines, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 91 Literaturangaben.
Abstract (Originalsprache)
Objective
To investigate the effects of Alogliptin in chemical-induced post-menopausal osteoporosis. Methodology The binding affinity of alogliptin with osteogenic proteins was analysed in silico. The effect of alogliptin on osteogenic proteins and mineralization of osteoblastic cells was evaluated in UMR-106 cells. Further, in vivo anti-osteoporotic activity of alogliptin was evaluated in postmenopausal osteoporosis. Various bone turnover markers were assayed in serum. This followed the analysis of microarchitecture of bone, histology, and immunohistochemistry (IHC) of bone tissue.
Results
Docking scores showed that alogliptin has binding affinity for bone alkaline phosphatase (BALP), osteocalcin, and bone morphogenic protein (BMP-2). Alogliptin also enhanced mineralization of osteoblast cells, evidenced with increased ALP, osteocalcin, and BMP-2. Animal studies revealed significant elevation of bone formation markers, bone ALP, osteocalcin and BMP-2, and decreased bone resorption markers, receptor activator of NF-κβ (RANKL), cathepsin K (CTSK), tartrate resistant acid phosphatase (TRAcP5b) in VCD-induced post-menopausal osteoporosis. Micro computed tomography (μCT) analysis and histology of femur bone and lumbar vertebrae demonstrated decrease in trabecular separation and improved bone density. IHC of femur showed reduced DPP4 enzyme.
Conclusions
Alogliptin increased mineralization in osteoblast cells. It had beneficial effects also altered bone turnover markers, repaired the trabecular microstructure, improved bone mineral density, and exhibited bone forming capacity targeting DPP-4 enzyme in postmenopausal osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
- Department of Molecular Medicine, School of Interdisciplinary Science and Technology, Jamia Hamdard, New Delhi 110062, India.
ORCID-Profile: Abul Kalam Najmi, Mohammad Ahmed Khan
Zitieren
APA
Ahmed, F., Ahmad, S. S., Alam, M. M., Shaquiquzzaman, M., Altamish, M., Krishnan, A., Vohora, D., Najmi, A. K., & Khan, M. A. (2025). Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico , in vitro, and in vivo analysis. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae112
Vancouver
Ahmed F, Ahmad SS, Alam MM, Shaquiquzzaman M, Altamish M, Krishnan A, et al. Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico , in vitro, and in vivo analysis. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgae112
BibTeX
@article{Ahmed2025,
author = {Ahmed, Faraha and Ahmad, Syed Sufian and Alam, Mohammad Mumtaz and Shaquiquzzaman, Mohammad and Altamish, Mohammad and Krishnan, Anuja and Vohora, Divya and Najmi, Abul Kalam and Khan, Mohammad Ahmed},
title = {Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico , in vitro, and in vivo analysis},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgae112}
}
EUVIMED